Remove Communication Remove Documentation Remove White Paper
article thumbnail

How ICH E6 (R3) is changing clinical trials

Pharmaceutical Technology

Integrated CDMS solutions also facilitate smoother communication and coordination between stakeholders, enabling faster, data-driven decision-making – all increasingly crucial for maintaining oversight and regulatory compliance. To explore how Zelta can support your organization’s clinical data management needs, download the document below.

article thumbnail

Cell and gene therapy: The vital role of logistics

Pharmaceutical Technology

In addition, documentation of the material is required, along with clearly defined next steps for modification and expansion. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Sign up for our daily news round-up!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GSK’s Blenrep US comeback hindered by eye safety concerns

Pharmaceutical Technology

Robert Barrie July 16, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Shares in London-listed GSK closed 1.19% down following the document release. Syngene’s expertise in the field is covered in this white paper. 1take1shot via Shutterstock. You will receive an email shortly.

article thumbnail

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Pharmaceutical Technology

The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech.

article thumbnail

Can rare disease research in the US thrive under the new administration?

Pharmaceutical Technology

Comstock said it is not yet clear if the report will be turned into an official agency guidance document, but it will be made publicly available. Give your business an edge with our leading industry insights. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

FDA
article thumbnail

GSK’s Blenrep faces setback as FDA cancer committee votes against approval

Pharmaceutical Technology

Syngene’s expertise in the field is covered in this white paper. The concern of ocular toxicity was first highlighted in a document published ahead of the ODAC meeting that took place on 17 July. Syngene’s expertise in the field is covered in this white paper. You will receive an email shortly.

FDA
article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)